Hesperidin
Identification
- Name
- Hesperidin
- Accession Number
- DB04703
- Description
Hesperidin is a flavan-on glycoside found in citrus fruits.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Hesperidin (DB04703)
- Weight
- Average: 610.5606
Monoisotopic: 610.189770418 - Chemical Formula
- C28H34O15
- Synonyms
- (S)-(−)-hesperidin
- Cirantin
- Ciratin
- Hesperetin 7-O-rutinoside
- Hesperidin
- Hesperidina
- Hesperidoside
- External IDs
- NDI 590
- NSC-44184
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UAurora kinase B Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cilobana Cpa Tab Hesperidin (75 mg) + Ascorbic acid (150 mg) + Bromelains (4 mg) + Citrus bioflavonoids (75 mg) + Vitamin A (10000 unit) Tablet Oral Anabolic Laboratories Inc. 1968-12-31 1996-10-02 Canada 
Rose Hips 500plus Nu Life Hesperidin (100 mg) + Ascorbic acid (500 mg) + Citrus bioflavonoids (100 mg) + Rutin (50 mg) Tablet Oral Nu Life Nutrition Ltd. 1972-12-31 2005-03-15 Canada Special C Hesperidin (32.5 mg) + Ascorbic acid (333 mg) + Citrus bioflavonoids (12.5 mg) Capsule Oral Anabolic Laboratories Inc. 1963-12-31 1996-10-02 Canada
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as flavonoid-7-o-glycosides. These are phenolic compounds containing a flavonoid moiety which is O-glycosidically linked to carbohydrate moiety at the C7-position.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Flavonoids
- Sub Class
- Flavonoid glycosides
- Direct Parent
- Flavonoid-7-O-glycosides
- Alternative Parents
- 4'-O-methylated flavonoids / 3'-hydroxyflavonoids / 5-hydroxyflavonoids / Flavanones / Phenolic glycosides / O-glycosyl compounds / Disaccharides / Chromones / Methoxyphenols / Phenoxy compounds show 14 more
- Substituents
- 1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 3'-hydroxyflavonoid / 4p-methoxyflavonoid-skeleton / 5-hydroxyflavonoid / Acetal / Alcohol / Alkyl aryl ether / Anisole show 33 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- rutinoside, disaccharide derivative, 3'-hydroxyflavanones, monomethoxyflavanone, flavanone glycoside, dihydroxyflavanone (CHEBI:28775) / flavanones (C09755)
Chemical Identifiers
- UNII
- E750O06Y6O
- CAS number
- 520-26-3
- InChI Key
- QUQPHWDTPGMPEX-QJBIFVCTSA-N
- InChI
- InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
- IUPAC Name
- (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3,4-dihydro-2H-1-benzopyran-4-one
- SMILES
- COC1=CC=C(C=C1O)[[email protected]@H]1CC(=O)C2=C(O1)C=C(O[[email protected]@H]1O[[email protected]](CO[[email protected]@H]3O[[email protected]@H](C)[[email protected]](O)[[email protected]@H](O)[[email protected]]3O)[[email protected]@H](O)[[email protected]](O)[[email protected]]1O)C=C2O
References
- Synthesis Reference
Hiromi Hijiya, Toshio Miyake, ".alpha.-glycosyl hesperidin, and its preparation and uses." U.S. Patent US5652124, issued June, 1983.
US5652124- General References
- Not Available
- External Links
- KEGG Drug
- D01038
- KEGG Compound
- C09755
- PubChem Compound
- 10621
- PubChem Substance
- 46506898
- ChemSpider
- 10176
- BindingDB
- 61776
- 5281
- ChEBI
- 28775
- ChEMBL
- CHEMBL449317
- ZINC
- ZINC000008143568
- PharmGKB
- PA449867
- PDBe Ligand
- H1N
- Wikipedia
- Hesperidin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Lower Extremity Lymphedema 1 4 Completed Treatment Venous Insufficiency 1 4 Not Yet Recruiting Treatment Pelvic Congestive Syndrome / Pelvic Varices / Venous Disease 1 3 Completed Prevention Osteoporosis, Osteopenia 1 3 Unknown Status Treatment Chronic Venous Insufficiency (CVI) / Diseases 1 2 Unknown Status Treatment Endothelial Dysfunction / Metabolic Syndromes 1 2 Withdrawn Treatment BMI >30 kg/m2 / Insulin Resistance 1 0 Not Yet Recruiting Treatment Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) 1 Not Available Not Yet Recruiting Not Available Hemorrhoids, Internal 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Suspension Oral 1000 mg Tablet, coated Oral 500 mg Capsule, liquid filled Oral 500 mg Capsule Oral Tablet, coated Oral 450 mg Tablet, coated Oral 900 mg Powder, for suspension Oral 900 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.69 mg/mL ALOGPS logP -0.27 ALOGPS logP -0.31 ChemAxon logS -2.4 ALOGPS pKa (Strongest Acidic) 9.51 ChemAxon pKa (Strongest Basic) -3.6 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 15 ChemAxon Hydrogen Donor Count 8 ChemAxon Polar Surface Area 234.29 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 140.77 m3·mol-1 ChemAxon Polarizability 58.76 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein serine/threonine/tyrosine kinase activity
- Specific Function
- Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in...
- Gene Name
- AURKB
- Uniprot ID
- Q96GD4
- Uniprot Name
- Aurora kinase B
- Molecular Weight
- 39310.195 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on September 11, 2007 11:49 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates